

Press Release

Martin Kunze
Corporate Communications

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2115
F +49 6172 608-2294
martin.kunze@fresenius.com
www.fresenius.com

February 19, 2020

Fresenius Helios acquires first hospital in Bogotá, continuing expansion in Colombia's private hospital market

Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, has signed an agreement to acquire Clínica de la Mujer in Bogotá, further expanding the company's presence in Colombia's attractive private hospital market. Following the acquisitions in Medellín and Cali in the two previous years, this is the company's first acquisition in Colombia's capital city.

Clínica de la Mujer is located in a prime residential area of Bogotá, Colombia's largest city, with a population of 7.4 million. The hospital puts a special focus on gynecology, pediatrics and obstetrics, helping mothers to deliver about 3,000 babies annually, while also offering a broad range of other medical specialties and services. It has approximately 80 beds and five operating rooms, and generated sales of about €20 million in 2019.

Both parties have agreed not to disclose the terms of the acquisition. The transaction is expected to close in the second quarter of 2020, pending antitrust clearance. Fresenius expects the acquisition of Clínica de la Mujer to be accretive to Group net income¹ in fiscal year 2020.

#

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA

Fresenius is a global health care group, providing products and services for dialysis, hospital and outpatient medical care. In 2018, Group sales were €33.5 billion. On September 30, 2019, the Fresenius Group had 292,635 employees worldwide.

For more information visit the Company's website at www.fresenius.com.

Follow us on Social Media: www.fresenius.com/socialmedia

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Stephan Sturm (Chairman), Dr. Francesco De Meo, Rachel Empey, Dr. Jürgen Götz, Mats Henriksson, Rice Powell, Dr. Ernst Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick